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How effective 
is desmopressin for primary
nocturnal enuresis?
■ EVIDENCE-BASED ANSWER
Desmopressin reduces the number of nights ofprimary noctural enuresis by at least 1 per
week, and increases the likelihood of “cure”
(defined as 14 consecutive dry nights) while treat-
ment is continued (number needed to treat
[NNT]=5–6) (strength of recommendation [SOR]:
A, based on meta-analysis). Evidence suggests
that the benefits of desmopressin are temporary,
with a high relapse rate once treatment is discon-
tinued (SOR: B). However, long-term therapy with
occasional weaning attempts is a safe option
(SOR: B). Evidence is inadequate to judge the 
relative efficacy of the nasal vs oral forms of
desmopressin (SOR: C).
■ EVIDENCE SUMMARY
Desmopressin is an analogue of the natural 
pituitary hormone vasopressin acetate. It pro-
duces an antidiuretic effect, resulting in increased
reabsorption of water from the kidney, a reduced
volume of more concentrated urine entering the
bladder, and a reduced 24-hour urine production.1,2
Desmopressin is available in a nasal spray 
(10 µg/spray) and an oral tablet (0.2 mg), and is
most often prescribed as 1 to 2 sprays per nostril
or 1 to 3 tablets at bedtime, regardless of age 
or weight.1
A Cochrane review1 of 16 randomized con-
trolled trials found nasal desmopressin to be
better than placebo in reducing the number of
wet nights per week (mean 1.34 fewer wet
nights/week; 95% confidence interval,
1.11–1.57). Desmopressin at doses of 20 µg, 40
µg, and 60 µg similarly increased the likelihood
of a cure (14 consecutive dry nights during
treatment) in 3 trials reporting this outcome
(relative risk for failure to achieve 14 dry nights
with 20 µg=0.84; NNT for cure=5.6).3 No differ-
ence was found in cure rates after treatment
was stopped. Data were insufficient to judge the
effectiveness of the oral versus nasal route of
desmopressin.1
One randomized controlled trial found a 
linear dose response for oral desmopressin in
reducing wet nights. After 2 weeks of treat-
ment, the number of wet nights was decreased
by 27%, 30%, and 40% at doses of 0.2 mg, 
0.4 mg, and 0.6 mg, respectively,  compared
with 10% with placebo.1
Snajderova and colleagues studied desmo-
pressin as a long-term treatment for 55 children
with primary nocturnal enuresis. Intranasal
desmopressin was titrated upward until bedwet-
ting stopped (7–21 µg; 89.1% responders); 
children in whom no response occurred to a 
maximum of 28 µg were excluded. Every 
3 months, a weaning attempt was made; if relapse
occurred, the previous successful dose was rein-
stated. At the end of each of the 3 years, the num-
ber of responders remained higher (72.7%,
70.9%, 61.6%) than the spontaneous cure rate of
15%.4
The Swedish Enuresis Trial (SWEET) demon-
strated a similar outcome in an open-label study
of 399 children.5
The main side effects of desmopressin are
nasal discomfort, nose bleeds, headache,
abdominal pain, rash, and (rare but serious)
water intoxication. Restrict fluid to 240 mL 
(8 oz) on nights desmopressin is given.1
■ RECOMMENDATIONS FROM OTHERS
A University of California at San Diego Medical
Group Guideline recommends using desmopressin
for primary nocturnal enuresis in children aged
>5 years when it occurs frequently and causes
distress, as well as under specific circumstances,
such as when a child shares a room or goes to
camp, or a sleepover. 
Therapy begins at 10 µg (1 nasal puff) 
each night, increasing weekly to a maximum 
of 40 µg. Younger children should be reassured,
encouraged to limit fluids and void before 
bedtime, partake in the responsibility to change
bedding, and be praised for dry nights.6
The American Academy of Pediatrics also
emphasizes support and encouragement of the
child, and reassurance that the problem will get
better in time. For children aged ≥7 years, 
alarm systems or bladder-stretching exercises
might help.7
Sabina Diehr, MD, Medical College of Wisconsin,
Milwaukee; Caryn Scoville, Public Services Librarian,
University of Missouri–Columbia.
■ CLINICAL COMMENTARY
Primary nocturnal enuresis can be challenging
for the primary care physician, frustrating for
the patient’s parents, and embarrassing for the
child. The physician’s role is to help the child
and parents realize that almost all children
eventually maintain nocturnal continence
whether or not pharmacotherapy is used.  
Nonpharmacologic interventions, such as
behavioral modification (eg, use of a nocturnal
conditioning alarm with a moisture sensor) may
be more acceptable to families, at least as a first
attempt at therapy. In my experience, however,
many children sleep through these alarms.
The decision to use medication should be
made by a well-informed and motivated child
and their parents. They should understand the
limitations and expectations of pharmaco-
therapy. The authors of this clinical inquiry
have provided the physician with an excellent
summary of the evidence for the efficacy of
desmopressin.
Children with enuresis associated with sleep
arousal disorder should theoretically respond
to older forms of pharmacotherapy, such as
imipramine. However, due to potential toxicity,
many clinicians are reluctant to use tricyclic
antidepressants in their patients. The efficacy
and low toxicity of desmopressin makes it an
attractive choice for pharmacotherapy in
enuretic children.  
David M. Bercaw, MD, Christiana Care Health
System, Wilmington, Del
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PATIENT ORIENTED EVIDENCE THAT MATTERS
Watch for these POEMs
coming soon
Blood cultures not helpful
in the management 
of community-acquired pneumonia
Low-dose warfarin for recurrent
thromboembolism
Selective aldosterone blockade
following myocardial infarction
POEMs
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